natgillin/translations-raw huggingface dataset:
Common: Tumour lysis syndrome*
Pogosti: sindrom tumorske lize
Common: Uncommon:
pogosti:
Common: Uncommon:
pogosti: občasni:
Common: Uncommon: Rare:
pogosti:
Common: Uncommon: Rare:
Pogosti: Občasni: Redki:
Common: upper respiratory tract infection (including sinusitis, nasopharyngitis and rhinitis), otitis (media and externa), haematuria, pyrexia.
Pogosti: okužba zgornjih dihal (vključno s sinusitisom, nazofaringitisom in rinitis), vnetje ušesa (srednjega in zunanjega), hematurija, zvišana telesna temperatura.
Common: Upper respiratory tract infection, nasopharyngitis Uncommon: Cellulitis, dental infections, herpes zoster, viral upper respiratory tract infection, vulvovaginal mycotic infection
Pogosti: okužbe zob, okužbe zgornjih dihal, nazofaringitis Občasni: celulitis, herpes zoster, virusne okužbe zgornjih dihal
Common: urinary incontinence
Pogosti: urinska inkontinenca
Common: urinary urgency (1.3% vs.
Pogosti: siljenje na uriniranje (1.3% vs.
Common: Vertigo
Pogosti: vrtoglavica
Common: Vertigo
Pogosto: vrtoglavica
Common: vertigo (2.7% vs.
Pogosti: vrtoglavica (2.7% vs.
Common: Vertigo.
pogosti: vrtoglavica.
Common: Very rarely:
Pogosti:
Common: Very rarely:
Zelo pogosti:
Common: Vision blurred, cataract;
pogosti: zamegljen vid, katarakta;
Common: visual disturbances, blindness
Pogosti: motnje vida, slepota
Common: Vomiting
Pogosti: bruhanje
Common: Vomiting, abdominal pain and diarrhoea
Pogosti: bruhanje, bolečine v trebuhu in diareja
Common: Vomiting, diarrhoea*, dyspepsia*, abdominal pain, abnormal stools, nausea, abdominal distension
Pogosto: bruhanje, diareja*, dispepsija*,bolečine v trebuhu, nenormalno blato, navzea, abdominalna distenzija
Common: vomiting, diarrhoea, abdominal pain upper,
pogosti: bruhanje, diareja, bolečina v zgornjem delu trebuha
Common: Vomiting, Diarrhoea1,3, Nausea3, Anorexia1, Liver Function Tests Abnormal, Cheilitis2, Dry Mouth2,3, Constipation, Flatulence,
bruhanje, driska1,3, slabost3, anoreksija1, nenormalni izvidi pri testiranju jetrne funkcije, vnetje ustnice2, suha usta2,3, zaprtje, vetrovi pankreatitis1,3, odpoved jeter, bolezni prebavil1
Common: vomiting, nausea
Pogosti: bruhanje, navzea
Common: Vomiting, nausea, abdominal pain Uncommon: Diarrhoea
Pogosti: bruhanje, slabost, bolečine v trebuhu Občasni: driska
Common: Weight decreased*, decreased appetite*
Pogosti: zmanjšanje telesne mase*, zmanjšanje apetita
Common: Weight decreased, body temperature increased
Pogoste: Izguba telesne teže, zvišana telesna temperatura
Common: Weight decreased, weight increased.
pogosti: zmanjšanje telesne mase, povečanje telesne mase.
Common: Weight gain
Pogosti: pridobivanje telesne mase
Common: Weight Gain, SGOT Increased, SGPT Increased, Lactic Dehydrogenase Increased, Creatinine Increased, Hypoproteinaemia,
Pogosti: povečanje telesne mase, zvišan SGOT, zvišan SGPT, zvišana laktat- dehidrogenaza, zvišan kreatinin, hipoproteinemija
Common: Wound complication*
Pogosti: zapleti z rano
Common: Wound infection
Pogosti: okužba rane
Common: ≥ 1/100 to < 1/10 Uncommon: ≥ 1/1,000 to < 1/100 Rare: ≥ 1/10,000 to < 1/1,000 Very rare: < 1/10,000
Pogosti: ≥ 1/100 do < 1/10 Občasni: ≥ 1/1.000 do < 1/100 Redki: ≥ 1/10.000 do < 1/1.000 Zelo redki: < 1/10.000
Common: ≥ 1/100 to < 1/10 Uncommon: ≥1/1,000 to < 1/100 Rare: ≥1/10,000 to < 1/1,000
Pogosti: ≥ 1/100 do < 1/10 Občasni: ≥ 1/1.000 do < 1/100 Redki: ≥ 1/10.000 do < 1/1.000
Common:  1/100 to < 1/10
pogosti:  1/100 do < 1/10
Common: 1/100 to <1/10 Uncommon: 1/1,000 to <1/100
Pogosti:  1/100 in < 1/10 Občasni:  1/1.000 in < 1/100
CommonA
PogostiA
Commonly Asked Questions Other Information
Pogosto zastavljena vprašanja Druge informacije
Commonly observed adverse reactions in clinical trials (1.2% of treated dogs) were mild and transient skin reactions such as erythema or alopecia at the application site.
Pogosto opaženi neželeni učinki med kliničnimi testiranji (1,2% zdravljenih psov) so bile blage in prehodne kožne reakcije na mestu nanosa kot naprimer rdečina ali izpadanje dlake.
Commonly observed adverse reactions in clinical trials (1.6% of treated dogs) were mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling.
Običajno opaženi neželeni učinki med kliničnimi testiranji (1,6% zdravljenih psov) so bili blagi in prehodni gastrointestinalni učinki, kot na primer diareja, bruhanje, pomanjkanje teka in slinjenje.
Commonly observed adverse reactions in clinical trials (1.6% of treated dogs) were mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling.
Običajno opaženi neželeni učinki med kliničnimi testiranju (1,6% zdravljenih psov) so bili blagi in prehodni gastrointestinalni učinki, kot na primer diareja, bruhanje, pomanjkanje teka in slinjenje.
Commonly observed adverse reactions in clinical trials were mild and transient skin reactions at the application site (2.2% of treated cats), such as erythema and pruritus or alopecia.
Pogosto opaženi neželeni učinki med kliničnimi so bile blage in prehodne kožne reakcije na mestu nanosa (2,2% zdravljenih mačk) kot na primer rdečina in srbenje ali izpadanje dlake.
Commonly observed adverse reactions in clinical trials were mild and transient skin reactions at the application site (2.2% of treated cats), such as erythema and pruritus or alopecia.
Pogosto opaženi neželeni učinki med kliničnimi testiranji so bile blage in prehodne kožne reakcije na mestu nanosa (2,2% zdravljenih mačk) kot na primer rdečina in srbenje ali izpadanje dlake.
Commonly observed adverse reactions such as erythema or alopecia in clinical trials (1.2% of treated dogs) were mild and transient skin reactions at the application site.
Pogosto opaženi neželeni učinki med kliničnimi testiranji (1,2% zdravljenih psov) so bile blage in prehodne kožne reakcije na mestu nanosa kot na primer rdečina ali izpadanje dlake.
Commonly reported post-vaccination reactions are a diffuse swelling and/or hardened nodule, accompanied by pain, at the site of vaccination.
Pogosta reakcija na cepljenje je difuzna boleča oteklina in/ali zatrdlina na mestu vboda.
Commonly reported reactions included redness and/or induration/swelling/pain at the injection site, fever equal to or greater than 38 °C, irritability, drowsiness, loss of appetite, insomnia, diarrhoea and vomiting.
Pogosto poročane reakcije so bile rdečina in/ali otrdlina/oteklina/bolečina na mestu vbrizganja, vročina  38 °C, razdražljivost, zaspanost, izguba teka, nespečnost, driska in bruhanje.
Commonly reported side effects
Pogosto prijavljeni neželeni učinki:
Commonly reported side effects (may affect up to 1 in 10 people):
Pogosto poročani neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov):
Commonly reported side effects (may affect up to 1 in 10 people):
Pogosto pročani neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov):
Commonly reported side effects are mild to moderate shortness of breath (dyspnoea), productive cough, throat irritation and dry throat.
Neželeni učinki, o katerih bolniki pogosto poročajo, so blaga do zmerna kratka sapa (dispneja), kašelj z izkašljevanjem izmečka, vnetje žrela in suho žrelo.
Commonly reported side effects:
Pogosti neželeni učinki:
Commonly reported side effects:
Pogosto prijavljeni neželeni učinki:
Commonly seen side effects were related to the way the medicine works, such as increased genital and, to a smaller degree, urinary tract infection (infection of the structures that carry urine), and are considered to be manageable.
Pogosti neželeni učinki so bili povezani z načinom delovanja zdravila, npr. povečane okužbe spolovil in v nekoliko manj primerih okužbe sečil (okužba struktur, po katerih se prenaša urin), vendar jih je bilo mogoče obvladati.
Commonly seen side effects were related to the way the medicine works, such as increased genital and, to a smaller degree, urinary tract infection (infection of the structures that carry urine), and are considered to be manageable.
Pogosti neželeni učinki so povezani z načinom delovanja zdravila, npr. povečane okužbe spolovil in v nekoliko manj primerih okužbe sečil (okužba struktur, po katerih se prenaša urin), vendar jih je mogoče obvladati.
Commonly some patients (4% or less) have experienced headache, uncommonly fevers and flu like symptoms joint and muscle pains; prolapse of the womb; pain on intercourse in females; erection difficulties; increase in sweating; feeling sick; stomach and bowel symptoms; ringing in the ears; flushing; tiredness; dizziness; migraine; pins and needles; insomnia; depression; loss of appetite; swollen glands; bacterial, viral and fungal infections (e.g. cold sores); vaginal infection including thrush; cough and colds with sore throat.
Pogosto se je pri nekaterih bolnikih (4% ali manj) pojavil glavobol, občasno zvišana telesna temperatura in gripi podobni simptomi in bolečine v mišicah in sklepih; prolaps maternice; bolečine ob spolnem odnosu pri ženskah; motnje erekcije; povečano potenje; slabost; simptomi v želodcu in trebuhu; zvonjenje v ušesih; rdečica; utrujenost; omotica; migrena; mravljinčenje; nespečnost; depresija; pomanjkanje apetita; otekle žleze; bakterijske, virusne in glivične okužbe (npr. herpesna okužba v ustih); okužbe v nožnici vključno s kandidazo; kašelj in prehlad z vnetim žrelom.
Commonly susceptible species
Organizmi, ki so pogosto občutljivi na učinkovino
Commonly susceptible species:
Pogosto občutljive bakterijske vrste:
Commonly used medicinal products in patients with multiple sclerosis, intramuscular interferon beta-1a and glatiramer acetate, were clinically tested for potential interactions with dimethyl fumarate and did not alter the pharmacokinetic profile of dimethyl fumarate.
Zdravili, ki se pri bolnikih z multiplo sklerozo pogosto uporabljajo, intramuskularni interferon beta-1a in glatiramer acetat, so klinično preskusili glede možnih medsebojnih delovanj z dimetilfumaratom; spremembe farmakokinetičnega profila dimetilfumarata niso ugotovili.
Commonly, a reduction in the concentration of the blood protein albumin will occur during treatment.
Pogosto je med zdravljenjem prišlo do zmanjšanja koncentracije krvne beljakovine albumin.
Commonly, mild to moderate injection site swelling may develop in pigs.
Pogosto se pri prašičih lahko pojavi blaga do zmerna oteklina na mestu dajanja.
Community acquired pneumonia
zunajbolnišnične pljučnice,
Community-acquired pneumonia (an infection of the lungs that is caught outside of hospital).
„Zapletena“ pomeni, da je okužbo težko zdraviti); zunajbolnišnične pljučnice (okužbe pljuč, pridobljene zunaj bolnišnice).
Community-acquired pneumonia, mild or moderate (see section 4.4).
Blage ali zmerne pljučnice, dobljene v domačem okolju (glejte poglavje 4.4).
Community-acquired pneumonia, mild or moderate,
plučnica, dobljena v domačem okolju, blaga ali zmerna,
Community-acquired pneumonia: 800 mg once a day for 7 to 10 days,
Pljučnica, dobljena v domačem okolju: 800 mg enkrat na dan od 7 do 10 dni.
Comorbidities associated with advanced age, performance status and the likely tolerability to chemotherapy should therefore be thoroughly evaluated prior to the initiation of treatment in the elderly (see sections 4.2 and 5.1).
Sočasne bolezni, povezane z višjo starostjo, stanjem zmogljivosti in prenašanjem kemoterapije, je zato treba pri starejših pred začetkom zdravljenja temeljito oceniti (glejte poglavji 4.2 in 5.1).
Comparable exposure (AUC and Cmax) was demonstrated in healthy subjects following administration of daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection.
Pokazalo se je, da je po odmerjanju daptomicina s 30-minutno intravensko infuzijo ali z 2-minutno intravensko injekcijo izpostavljenost zdravilu (AUC in Cmax) medsebojno primerljiva.
Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1,000 and 500 cells/µl.
Primerljiva intenzivnost kemoterapije v skupini z epoetinom alfa in v skupini s placebom v preskušanjih s kemoterapijo je bila dokazana s podobno površino pod krivuljo števila nevtrofilcev v odvisnosti od časa pri bolnikih, zdravljenih z epoetinom alfa, in pri bolnikih, ki so dobivali placebo, kot tudi s podobnim deležem bolnikov v skupinah, zdravljenih z epoetinom alfa in s placebom, katerih absolutno število nevtrofilcev je padlo pod 1.000 in 500 celic/µl.
Comparable results were seen at doses above 3 mg in adolescents, although too few patients aged below 15 years were studied to clearly establish an effect in this younger age group.
Primerljivi rezultati so bili ugotovljeni tudi pri mladostnikih ob jemanju odmerkov, večjih od 3 mg, čeprav je bilo v študijah udeleženih premalo bolnikov, mlajših od 15 let, da bi lahko jasno določili učinek v tej mlajši starostni skupini.
Comparable to the overall population, median duration of response was increased with nivolumab vs. docetaxel for patients with no PD-L1 expression (18.3 months vs.
V primerjavi s celokupno populacijo je bilo mediano trajanje odziva daljše pri nivolumabu v primerjavi z docetakselom pri bolnikih brez ekspresije PD-L1 (18,3 meseca v primerjavi s 5,6 meseca) in pri bolnikih z ekspresijo PD-L1
Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with follitropin alfa compared with urinary FSH.
Primerjalna klinična preskušanja so pokazala, da potrebuje bolnik v povprečju nižji skupni odmerek in krajše trajanje zdravljenja s folitropinom alfa kot z urinarnim FSH.
Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with follitropin alfa compared with urinary FSH.
Primerjalne klinične študije so pokazala, da potrebuje bolnik v povprečju nižji skupni odmerek in krajše trajanje zdravljenja s folitropinom alfa kot z urinarnim FSH.
Comparative data according to YMDD status were also available for histological assessment but only up to three years.
Na voljo so tudi primerjalni podatki o histološki oceni glede na status YMDD, vendar samo za obdobje do treh let.
Comparative efficacy data from randomised clinical studies are not yet available.
Primerjalnih podatkov o učinkovitosti zdravila iz randomiziranih kliničnih študij še ni na voljo.
Comparative Phase Washout Phase
Primerjalna faza Faza spiranja
Comparative safety data from randomised clinical trials are not yet available.
Primerjalni podatki o varnosti iz randomiziranih kliničnih preizkušanj še niso na voljo.
Comparator
primerjalno zdravilo
Compare both sides of the mixing window to the photos below by holding the pen against the page.
Primerjajte obe strani okenca za mešanje s spodnjimi fotografijami tako, da podržite peresnik ob strani.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Enviage 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je Enviage po 12 tednih zdravljenja v odmerku 300 mg znižal sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Rasilez 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je zdravilo Rasilez po 12 tednih zdravljenja v odmerku 300 mg znižalo sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Riprazo 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je zdravilo Riprazo po 12 tednih zdravljenja v odmerku 300 mg znižalo sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Sprimeo 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je zdravilo Sprimeo po 12 tednih zdravljenja v odmerku 300 mg znižalo sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a diuretic (hydrochlorothiazide - HCTZ), Tekturna 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je Tekturna po 12 tednih zdravljenja v odmerku 300 mg znižal sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
V primerjavi z diuretikom hidroklorotiazidom je aliskiren po 12 tednih zdravljenja v odmerku 300 mg znižal sistolični/diastolični krvni tlak za 17,0/12,3 mmHg, hidroklorotiazid v odmerku 25 mg pa za 14,4/10,5 mmHg.
Compared to a patient with a body weight of 65 kg, the rivastigmine steady-state concentrations in a patient with a body weight of 35 kg would be approximately doubled, while for a patient with a body weight of 100 kg the concentrations would be approximately halved.
V stanju dinamičnega ravnovesja so koncentracije pri bolniku s telesno maso 35 kg približno dvakrat tolikšne kot pri bolniku s telesno maso 65 kg, pri bolniku s telesno maso 100 kg pa pol manjše kot pri bolniku s telesno maso 65 kg.
Compared to both propofol and midazolam, patients were more easily roused, more cooperative and better able to communicate whether or not they had pain.
V primerjavi tako s propofolom kot z midazolamom so bolnike tudi lažje zbudili in so bili ti bolj kooperativni ter so lažje povedali, ali imajo bolečine ali ne.
Compared to Caucasian patients, Asian patients have an increased risk of severe and febrile neutropenia following treatment with ONIVYDE+5-FU/LV (see sections 4.8 and 5.2).
V primerjavi z bolniki bele rase imajo bolniki azijskega porekla po zdravljenju z zdraviloma ONIVYDE+5-FU/LV večje tveganje za hudo in febrilno nevtropenijo (glejte poglavji 4.8 in 5.2).
Compared to control subjects with normal hepatic function, the AUC and Cmax of nelfinavir were not significantly different in subjects with mild impairment but were increased by 62% and 22%, respectively in subjects with moderate hepatic impairment.
AUC in Cmax nelfinavirja se v primerjavi s kontrolno skupino z normalno funkcijo jeter, nista pomembno razlikovala od skupine z blago jetrno okvaro, v skupini z zmerno jetrno okvaro pa je bil AUC višji za 62 %, Cmax pa za 22 %.
Compared to controls, nelarabine caused increased incidences of foetal malformations, anomalies, and variations in rabbits when given at doses approximately 24 % of the adult human dose on a mg/m2 basis during the period of organogenesis.
V primerjavi s kontrolnimi učinkovinami je nelarabin pri plodovih kuncev povzročil večjo pojavnost malformacij, anomalij in variacij pri dajanju med obdobjem organogeneze v odmerkih, ki so na osnovi mg/m2 predstavljali približno 24 % odmerka za odrasle bolnike.
Compared to efavirenz 600 mg QD, Efavirenz Cmax ↔
v primerjavi s 600 mg efavirenza QD,
Compared to efavirenz 600 mg QD, Efavirenz Cmax ↔ Efavirenz AUCτ  17%
v primerjavi s 600 mg efavirenza QD, efavirenz Cmax ↔ efavirenz AUCτ  17
Compared to glimepiride as dual therapy with metformin (52 weeks)
V primerjavi z glimepiridom pri dvotirnem zdravljenju z metforminom (52 tednov)
Compared to glimepiride as dual therapy with metformin (52 weeks)
V primerjavi z glimepiridom v okviru dvotirnega zdravljenja z metforminom (52 tednov)
Compared to healthy controls, subjects with renal impairment demonstrated 1.6 – and 1.4-fold increases in AUC and Cmax, respectively and a half- life of about twice that of healthy subjects.
V primerjavi z zdravimi kontrolnimi osebami so pri bolnikih z ledvično okvaro ugotovili 1,6-kratno povečanje vrednosti AUC in 1,4-kratno povečanje vrednosti Cmax, medtem ko je bil razpolovni čas približno dvakrat daljši kot pri zdravih osebah.
Compared to healthy subjects with normal renal function (classified using the Modification of Diet in Renal Disease [MDRD] eGFR formula; eGFR ≥ 80 ml/min), the mean steady-state AUC of simeprevir was 1.62-fold higher (90% confidence interval: 0.73-3.6) in subjects with severe renal impairment (eGFR below 30 ml/min).
Povprečna vrednost AUC simeprevirja v stanju dinamičnega ravnovesja je bila pri bolnikih s hudo okvaro ledvic (z ocenjeno glomerulno filtracijo (eGFR) manj kot 30 ml/min) za 1,62-krat večja (90% IZ: 0,73-3,6) kot pri zdravih osebah z normalno ledvično funkcijo (opredeljeni s formulo za ocenjeno glomerulno filtracijo po metodi Modification of Diet in Renal Disease [MDRD] kot eGFR
compared to historical controls.
v primerjavi s prejšnjimi, kontrolnimi
compared to historical controls.
v primerjavi s prejšnjimi, kontrolnimi vrednostmi
Compared to patients treated with chemotherapy (paclitaxel, topotecan or PLD) alone in the recurrent platinum-resistant setting, patients who received bevacizumab at a dose of 10 mg/kg every 2 weeks (or 15 mg/kg every 3 weeks if used in combination with 1.25 mg/m2 topotecan on Days 1–5 every 3 weeks) in combination with chemotherapy and continued to receive bevacizumab until disease progression or unacceptable toxicity, had a statistically significant improvement in PFS.
V primerjavi z bolnicami, zdravljenimi samo s kemoterapijo (paklitakselom, topotekanom ali PLD), pri ponovitvi bolezni, rezistentni na platino, so imele bolnice, ki so prejemale bevacizumab v odmerku 10 mg/kg vsaka 2 tedna (ali 15 mg/kg vsake 3 tedne, če so ga uporabljali v kombinaciji z 1,25 mg/m2 topotekana od 1. do 5. dne vsake 3 tedne) v kombinaciji s kemoterapijo in nadaljevale z njegovim jemanjem do napredovanja bolezni ali nesprejemljive toksičnosti, statistično pomembno izboljšanje preživetja brez napredovanja bolezni.
Compared to patients treated with placebo, estimated glomerular filtration rate (eGFR) was observed to increase in patients treated with Tecfidera, including those patients with 2 consecutive occurrences of proteinuria (≥1+).
V primerjavi z bolniki, zdravljenimi s placebom, so opazili tudi zvišanje ocenjene stopnje glomerularne filtracije (eGFR, estimated glomerular filtration rate) pri bolnikih, zdravljenih z zdravilom Tecfidera, vključno z bolniki z 2 zaporednima pojavoma proteinurije (≥ 1+).
Compared to patients who were ADA negative, patients with an ADA positive status did not exhibit any difference in alirocumab exposure, efficacy, or safety, except for a higher rate of injection site reactions.
V primerjavi z ADA-negativnimi bolniki ni bilo pri ADA-pozitivnih bolnikih nobenih razlik v izpostavljenosti alirokumabu, njegovi učinkovitosti ali varnosti, razen višjega deleža reakcij na mestu injiciranja.
Compared to sitagliptin as triple therapy with metformin and sulphonylurea (52 weeks)
V primerjavi s sitagliptinom pri trotirnem zdravljenju z metforminom in sulfonilsečnino (52 tednov)
Compared to sitagliptin as triple therapy with metformin and sulphonylurea (52 weeks)
V primerjavi s sitagliptinom v okviru trotirnega zdravljenja z metforminom in sulfonilsečnino (52 tednov)
Compared to subjects with normal renal function, plasma concentrations of prucalopride after a single 2 mg dose were on average 25% and 51% higher in subjects with mild (ClCR 50-79 ml/min) and moderate (ClCR 25-49 ml/min) renal impairment, respectively.
V primerjavi z osebami z normalno ledvično funkcijo so bile plazemske koncentracije prukolaprida po enkratnem 2 mg odmerku pri osebah z blago (ClCR 50–79 ml/min) in zmerno (ClCR 25–49 ml/min) ledvično okvaro v povprečju 25 % oziroma 51 % višje.